BR0011521A - Composto nucleósidos de purina de 4' -c-etinila - Google Patents

Composto nucleósidos de purina de 4' -c-etinila

Info

Publication number
BR0011521A
BR0011521A BR0011521-5A BR0011521A BR0011521A BR 0011521 A BR0011521 A BR 0011521A BR 0011521 A BR0011521 A BR 0011521A BR 0011521 A BR0011521 A BR 0011521A
Authority
BR
Brazil
Prior art keywords
ethynyl
purine nucleoside
nucleoside compound
hydrogen atom
pyrimidine
Prior art date
Application number
BR0011521-5A
Other languages
English (en)
Other versions
BR0011521B8 (pt
BR0011521B1 (pt
Inventor
Hiroshi Ohrui
Eiichi Kodama
Satoru Kohgo
Hiroaki Mitsuya
Masao Matsuoka
Kenji Kitano
Original Assignee
Yamasa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp filed Critical Yamasa Corp
Publication of BR0011521A publication Critical patent/BR0011521A/pt
Publication of BR0011521B1 publication Critical patent/BR0011521B1/pt
Publication of BR0011521B8 publication Critical patent/BR0011521B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção "COMPOSTOS NUCLEóSIDOS DE PURINA DE 4'-C-ETINILA". Representados pela fórmula [I]: em que B representa uma base selecionada a partir do grupo que consiste de purina e seus derivados; X representa um átomo de hidrogênio ou um grupo hidroxila; e R representa um átomo de hidrogênio ou um resíduo de fosfato; e uma composição farmacêutica que contém qualquer dos compostos e um veículo farmaceuticamente aceitável. Preferencialmente, a composição é utilizada como agente anti-HIV ou uma droga para o tratamento da AIDS.
BRPI0011521A 1999-05-12 2000-05-11 compostos nucleósidos de purina de 4 -c-etinila BR0011521B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP13153999 1999-05-12
JP17492099 1999-06-22
JP31824699 1999-11-09
JP2000081117 2000-03-23
PCT/JP2000/003025 WO2000069877A1 (en) 1999-05-12 2000-05-11 4'-c-ethynyl purine nucleosides

Publications (3)

Publication Number Publication Date
BR0011521A true BR0011521A (pt) 2002-03-26
BR0011521B1 BR0011521B1 (pt) 2013-12-24
BR0011521B8 BR0011521B8 (pt) 2021-05-25

Family

ID=27471622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011521A BR0011521B8 (pt) 1999-05-12 2000-05-11 compostos nucleósidos de purina de 4 -c-etinila

Country Status (10)

Country Link
US (3) US6333315B1 (pt)
EP (2) EP1177201B1 (pt)
AT (2) ATE250622T1 (pt)
AU (2) AU4431300A (pt)
BR (1) BR0011521B8 (pt)
CA (2) CA2308677C (pt)
DE (2) DE60005502T2 (pt)
ES (1) ES2207504T3 (pt)
MX (1) MXPA01011517A (pt)
WO (2) WO2000069877A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069877A1 (en) * 1999-05-12 2000-11-23 Yamasa Corporation 4'-c-ethynyl purine nucleosides
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1438054A4 (en) * 2001-09-28 2006-07-26 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION
AU2003211483A1 (en) * 2002-02-15 2003-09-04 Yamasa Corporation 4'-c-cyano-2'-deoxypurine nucleosides
BRPI0407374A (pt) 2003-02-19 2006-01-10 Univ Yale Análogos de nucleosìdeo antiviral e métodos para tratar infecções virais, especialmente infecções de hiv
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
DE602005015466D1 (de) 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
NZ567272A (en) * 2005-09-26 2012-02-24 Pharmasset Inc Modified 4'-nucleosides as antiviral agents
MX2009003452A (es) 2006-10-10 2009-04-14 Medivir Ab Inhibidores nucleosidicos del vhc.
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6562908B2 (ja) 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MX391226B (es) 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
WO2018092728A1 (ja) 2016-11-16 2018-05-24 国立研究開発法人国立国際医療研究センター 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CA3087192A1 (en) * 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
CN118995846A (zh) * 2018-07-09 2024-11-22 默沙东有限责任公司 4’-乙炔基核苷类似物的酶促合成
EP3844164A1 (en) * 2018-08-30 2021-07-07 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
US12227536B2 (en) 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
EP3934760A1 (en) 2019-03-06 2022-01-12 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
US20220298160A1 (en) * 2019-08-28 2022-09-22 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
JP7719769B2 (ja) 2019-09-11 2025-08-06 ザ スクリプス リサーチ インスティテュート 抗ウイルスプロドラッグ及びその医薬組成物
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4493573A1 (en) 2022-03-15 2025-01-22 Rome Therapeutics, Inc. Compounds and methods for treating disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069877A1 (en) * 1999-05-12 2000-11-23 Yamasa Corporation 4'-c-ethynyl purine nucleosides

Also Published As

Publication number Publication date
EP1177202B1 (en) 2003-09-24
EP1177201A1 (en) 2002-02-06
CA2308192A1 (en) 2000-11-12
DE60005501D1 (de) 2003-10-30
ATE250622T1 (de) 2003-10-15
DE60005502T2 (de) 2004-06-24
EP1177202A1 (en) 2002-02-06
ES2207504T3 (es) 2004-06-01
EP1177201B1 (en) 2003-09-24
ATE250623T1 (de) 2003-10-15
CA2308677C (en) 2007-09-18
CA2308677A1 (en) 2000-11-12
BR0011521B8 (pt) 2021-05-25
AU4431300A (en) 2000-12-05
BR0011521B1 (pt) 2013-12-24
US20020022722A1 (en) 2002-02-21
WO2000069877A1 (en) 2000-11-23
AU4431200A (en) 2000-12-05
DE60005502D1 (de) 2003-10-30
US6291670B1 (en) 2001-09-18
MXPA01011517A (es) 2003-08-20
US6403568B1 (en) 2002-06-11
DE60005501T2 (de) 2004-06-24
CA2308192C (en) 2007-09-18
WO2000069876A1 (en) 2000-11-23
US6333315B1 (en) 2001-12-25

Similar Documents

Publication Publication Date Title
BR0011521B1 (pt) Compostos nucleósidos de purina de 4 -c-etinila
BG106569A (en) Purine derivatives
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
MY141512A (en) Purine derivatives
GB2230527B (en) Aminopyrimidine derivatives useful for treating cardiovascular disorders
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
DK1023308T3 (da) Inhibitorer af nukleosidmetabolisme
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
TR200103395T2 (tr) 13-metil eritromisin türevleri.
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
SE9904129D0 (sv) Novel compounds
ATE157252T1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
GB9426090D0 (en) Pharmaceutical compounds
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
AU7653300A (en) Carbocyclic nucleosides and process for obtaining such
IL147307A0 (en) Indolocarbazole alkaloid derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
CA2239053A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors
WO2001081315A3 (en) Amino-imidazole derivatives for treating cancer
AP2002002395A0 (en) Novel esters derived from nucleosides, preparation methods and pharmaceutical compositions containing them.

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 7A ANUIDADE(S), DE ACORDO COM A TABELA VIGENTE, REFERENTE A(S) GUIA(S) NO 220602446160.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: REFERENTE A RPI NO 2116 DE 26/07/2011

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08G Application fees: restoration [chapter 8.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/05/2020